Precision Medicine Asia (PREMIA)

What Precision Medicine Asia (PREMIA) does

Precision Medicine Asia (PREMIA) is a privately held specialty-services company founded in 2018 by Wenn Sun, Ph.D. and headquartered in Tokyo, with a regional holding entity in Hong Kong. PREMIA operates as a B2B partner to pharmaceutical and biotechnology companies developing targeted oncology therapies in Asia-Pacific, providing technical and regulatory expertise for companion diagnostic (CDx) development. The firm positions itself around three integrated offerings: (1) companion diagnostic development services with deep Japanese MHLW and broader Asian regulatory experience, (2) clinical-genomic screening infrastructure supporting comprehensive genomic profiling (CGP) across hospital systems, and (3) AI-powered clinical trial patient identification through its Lind Asia joint venture.

Underlying technology centers on a regional clinical-genomic screening network spanning Japan, Hong Kong, Taiwan, and China. PREMIA co-develops CDx products with diagnostic partners (notably AmoyDx) and navigates multi-party regulatory submissions with manufacturers and distributors (Riken Genesis, MBL). The platform's most recent commercial milestones include Japanese MHLW approvals of the AmoyDx Pan Lung Cancer PCR Panel for RYBREVANT/RYBROFAZ plus chemotherapy and as a drug-agnostic CDx for EGFR mutations, plus approval of the AmoyDx PIK3CA Mutation Detection Kit. A strategic partnership with Illumina Taiwan and Chang Gung Memorial Hospital underpins an Asia-wide clinical-genomic oncology database effort.

Revenue mechanics combine professional service fees for CDx development projects, licensing and milestone economics from CDx regulatory approvals, and recurring clinical-genomic infrastructure revenues from hospital systems and pharmaceutical partners. The customer base consists of pharmaceutical and biotech enterprises developing targeted therapies (anonmyized in source material as "Pharmaceutical Partners" and "Biotech Partners"), with named collaborators including AmoyDx, Riken Genesis, MBL, Illumina, Lind, and CGMH. PREMIA is founder-controlled, with no disclosed institutional funding rounds or external ownership, and discloses no revenue figures.

Name

Precision Medicine Asia (PREMIA)

Legal name

Precision Medicine Asia Inc.

Website

https://premia-inc.com

Company type

Private

Founded year

2018

Operating status

Operating

Short description

Precision Medicine Asia (PREMIA) is a Tokyo-based, privately held B2B services company that provides companion diagnostic development, regulatory expertise, and clinical-genomic screening infrastructure to pharmaceutical and biotechnology companies developing targeted oncology therapies across Asia-Pacific.

Ownership category

akta.pro rank

Product category

Companion Diagnostics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

akta.pro secondary industries

Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC), Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Companion Diagnostics (CDx) & Precision Medicine IVD (HLAHAAAJ), Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

Keywords

• Companion diagnostics
• Precision oncology
• Clinical genomics
• Pharmaceutical services
• Targeted therapy development

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Companion Diagnostics Development Services: Technical and regulatory expertise provided to pharmaceutical and biotech partners for CDx development in Asia. Revenue generated through service fees and potentially milestone payments during CDx development lifecycle.
2. Regulatory Approval Partnerships: Collaborative regulatory submissions with diagnostic partners (e.g., AmoyDx, Riken Genesis) for companion diagnostic approvals in Japan, generating revenue through partnership arrangements and co-development fees.
3. Clinical-Genomic Infrastructure Services: Providing clinical-genomic screening infrastructure to hospital systems and pharmaceutical partners for comprehensive genomic profiling of oncology patients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

PREMIA offers an integrated platform for the development of innovative oncology therapies and diagnostics in Asia, providing companion diagnostics (CDx) development services with extensive technical and regulatory expertise to pharmaceutical and biotech partners. The company supports targeted therapy development through clinical-genomic screening infrastructure and co-developed diagnostic products, including AmoyDx PCR panels and the AI-powered Lind Asia clinical trial screening platform.

Product overview

Precision Medicine Asia (PREMIA) operates as an integrated platform company for oncology therapy and diagnostics development in Asia. The core offerings include Companion Diagnostics (CDx) development services with extensive technical and regulatory expertise for pharmaceutical and biotech partners, supported by specific diagnostic products including the AmoyDx Pan Lung Cancer PCR Panel and AmoyDx PIK3CA Mutation Detection Kit. Through the Lind Asia joint venture, the company also provides AI-powered clinical trial screening capabilities. PREMIA's infrastructure spans clinical-genomic screening networks across Asia with partnerships for comprehensive genomic profiling.

Differentiator

Problem solved

Functional benefit

Products and services

• Companion Diagnostics (CDx) Development Services Integrated companion diagnostics development service providing technical and regulatory expertise for targeted oncology therapy development in Asia, supporting pharmaceutical and biotech partners through CDx development and MHLW approval processes.
• AmoyDx Pan Lung Cancer PCR Panel PCR-based companion diagnostic panel approved in Japan for lung cancer, identifying patients eligible for targeted therapies including EGFR mutations and amivantamab combination treatments.
• AmoyDx PIK3CA Mutation Detection Kit Mutation detection kit for identifying PIK3CA mutations in cancer patients, approved by Japanese MHLW for clinical use in Japan.
• Lind Asia AI-powered clinical trial screening platform jointly formed with Lind, combining PREMIA's regional clinical-genomic infrastructure with Lind's evidence-driven AI platform to accelerate patient identification for multinational clinical trials across Asia-Pacific.

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered core.

• LindcoreStrategic or Co-development Partner · 27 May 2026PREMIA and Lind formed Lind Asia, a strategic joint venture dedicated to revolutionizing clinical trial enrollment in the Asia-Pacific region. The joint venture combines PREMIA's regional clinical-genomic infrastructure with Lind's evidence-driven AI platform to accelerate patient identification for multinational trials.
• Riken Genesis Co., Ltd.coreStrategic or Co-development Partner · 28 April 2026Joint submission and approval with MHLW for AmoyDx Pan Lung Cancer PCR Panel as companion diagnostic for RYBREVANT or RYBROFAZ plus chemotherapy in Japan. Riken Genesis serves as regulatory partner for MHLW approvals.
• Amoy Diagnostics Co., Ltd. (AmoyDx)coreStrategic or Co-development Partner · 28 April 2026Long-standing partnership for companion diagnostic development and regulatory approval in Japan. Multiple co-development projects including AmoyDx Pan Lung Cancer PCR Panel approvals for EGFR mutations and Amivantamab combination therapies, as well as AmoyDx PIK3CA Mutation Detection Kit approval.
• Medical & Biological Laboratories Co., Ltd. (MBL)coreStrategic or Co-development Partner · 5 March 2026Three-way partnership with MBL and AmoyDx for regulatory approval of AmoyDx PIK3CA Mutation Detection Kit in Japan. MBL received MHLW approval for the kit as a result of close collaboration among MBL, AmoyDx, and PREMIA.
• Illumina Taiwan Biotechnology Co., Ltd.coreStrategic or Co-development Partner · 8 January 2026Strategic partnership to expand access to comprehensive genomic profiling (CGP) for all eligible oncology patients across the Chang Gung Memorial Hospital (CGMH) system. Partnership also aims to support creation of an Asia-wide clinical-genomic oncology database to advance precision oncology.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Personalis: US-based oncology genomics company with a CDx and pharma services business built around its NeXT Personal platform. Directly comparable as a smaller CDx co-development services company targeting pharma partnerships.
• Amoy Diagnostics (AmoyDx): China-based developer of PCR-based companion diagnostics, including the Pan Lung Cancer PCR Panel. Co-develops and manufactures the diagnostic products that PREMIA helps register in Japan, making it the closest operational peer and primary counterpart in PREMIA's CDx pipeline.
• Riken Genesis: Japanese diagnostics company specializing in genetic and oncology testing, partnered with PREMIA and AmoyDx on MHLW CDx submissions. Closely comparable regulatory/CDx business and a direct counterparty in PREMIA's Japanese approval pipeline.

Emerging players

• Tempus AI: AI-driven precision medicine platform combining multi-modal data, genomic profiling, and clinical trial enrollment. Closely comparable to the Lind Asia JV concept, though at much larger scale and global footprint.

Regional players

• Genetron Health: China-based oncology genomics and CDx company with NGS-based panels for therapy selection and MRD. Comparable to PREMIA in oncology CDx services for pharma/biotech, though focused on the China regulatory environment.
• SRL Inc. (H.U. Group Holdings): Japan's largest clinical laboratory network providing diagnostic testing and genomic profiling. Comparable as a Japan-based clinical-genomic infrastructure provider that could partner with or compete against PREMIA's hospital-side offerings.
• Burning Rock Biotech: China-based precision oncology company offering next-generation sequencing-based CDx and therapy selection assays for lung and other cancers. Directly comparable to PREMIA on disease focus (thoracic oncology) and CDx orientation, but anchored in mainland China rather than Japan.

Broad incumbents

• Guardant Health: Liquid biopsy and CDx developer serving pharma partners for therapy selection and clinical trials. Comparable as a CDx/precision oncology partner for pharma, with overlapping AI/clinical trial services offerings.
• Foundation Medicine (Roche): Global leader in comprehensive genomic profiling and CDx development, now part of Roche. Competes for the same pharma CDx co-development mandates and offers overlapping CGP services, but at much larger scale and primarily US/EU focused.
• Caris Life Sciences: US-based precision medicine company offering molecular profiling and CDx partnerships to pharma. Similar CDx co-development business model with global pharma clients, but operating primarily in the US market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precision Medicine Asia (PREMIA)